Cargando…

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of oral hypoglycemic agents which increase urinary glucose excretion by suppressing glucose reabsorption at the proximal tubule in the kidney. SGLT2 inhibitors lower glycated hemoglobin (HbA1c) by 0.6–0.8% (6–8 mmol/mol) without inc...

Descripción completa

Detalles Bibliográficos
Autor principal:	Saisho, Yoshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349723/ https://www.ncbi.nlm.nih.gov/pubmed/32403420 http://dx.doi.org/10.3390/diseases8020014

Ejemplares similares

Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
por: Saisho, Yoshifumi
Publicado: (2014)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
por: Sugiyama, Kazutoshi, et al.
Publicado: (2018)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu, Shuangbo, et al.
Publicado: (2019)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
por: Nauck, Michael A
Publicado: (2014)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes
por: Saisho, Yoshifumi
Publicado: (2016)

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
por: McGill, Janet B.
Publicado: (2014)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
por: Dąbrowski, Mariusz
Publicado: (2021)

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
por: Jung, Chang Hee, et al.
Publicado: (2014)

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
por: Thomas, Merlin C, et al.
Publicado: (2023)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
por: Kowalska, Klaudia, et al.
Publicado: (2022)

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
por: Huang, Keming, et al.
Publicado: (2023)

Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
por: Inaishi, Jun, et al.
Publicado: (2020)

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
por: Peppa, Melpomeni, et al.
Publicado: (2023)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
por: Saisho, Yoshifumi
Publicado: (2019)

Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes
por: Saisho, Yoshifumi
Publicado: (2018)

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018)

SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
por: Keller, Daria M., et al.
Publicado: (2022)

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
por: Li, Na, et al.
Publicado: (2020)

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Milder, Tamara Y., et al.
Publicado: (2019)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
por: Giorgino, Francesco, et al.
Publicado: (2020)

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cbcf591s6fdcfamug79cnnpp3e